Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia
Schizophrenia Bulletin · 2025
DOI: 10.1093/schbul/sbae190 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Schizophrenia Bulletin, 2025. Verfasst von Keith H Nuechterlein und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095-…. Hauptthemen laut MEDLINE: Schizophrenia, Nootropic Agents, Cognitive Dysfunction, Research Design. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Given the difficulties of developing cognitive enhancers for schizophrenia and demonstrating their efficacy, we welcome a review of the measurement procedures and the clinical trial design recommendations developed through the collaboration of academics, industry, National Institute of Mental Health (NIMH), and U.S.A. Food and Drug Administration (FDA) representatives during the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) process. We provide a perspective from investigators who helped to lead the MATRICS initiative. We acknowledge some of the practical challenges in the use of the MATRICS Consensus Cognitive Battery (MCCB) while pointing out that others are overstated. We suggest that a brief MCCB might be used in phase III trials when phase II results had shown no negative impact on any MCCB cognitive domain. The complexities of requiring a functional co-primary measure are discussed. For clinical trial research design to evaluate monotherapies that might have both antipsychotic and cognition-enhancing properties, we agree that the original MATRICS design recommendations may need to be revised, as those recommendations focused on the evaluation of potential adjunctive cognitive enhancers. Horan et al provide a thoughtful summary of the current challenges in obtaining approval for a new drug designed to enhance cognition in schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA 90095-6968, United States.
- Department of Psychology, UCLA, Los Angeles, CA 90095-1563, United States.
- VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, United States.
ORCID-Profile: Stephen R Marder
Zitieren
APA
Nuechterlein, K. H., Green, M. F., & Marder, S. R. (2025). Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbae190
Vancouver
Nuechterlein KH, Green MF, Marder SR. Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia. Schizophrenia Bulletin. 2025. doi:10.1093/schbul/sbae190
BibTeX
@article{Nuechterlein2025,
author = {Nuechterlein, Keith H and Green, Michael F and Marder, Stephen R},
title = {Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia},
journal = {Schizophrenia Bulletin},
year = {2025},
doi = {10.1093/schbul/sbae190}
}
EUVIMED